Enterprise value is the total economic value of a business, encompassing both its equity and its debt. It represents the price a buyer would need to pay to acquire the entire operating enterprise, assuming all existing obligations. In private equity, enterprise value is the starting point for nearly every valuation conversation, deal negotiation, and return calculation.
The basic formula is: Enterprise Value = Equity Value + Total Debt - Cash. If a company has $50M in equity value, $30M in debt, and $5M in cash, its enterprise value is $75M. The logic is that an acquirer who buys all the equity also inherits the debt obligations and receives the cash. Enterprise value captures the full picture.
In practice, the calculation includes several additional items that practitioners refer to as “debt-like” or “cash-like.” Working capital adjustments, unfunded pension liabilities, capital lease obligations, minority interests, and deferred revenue are all common adjustments that bridge the gap between a textbook EV calculation and the actual negotiated purchase price. These bridge items are one of the most contested areas in PE deal negotiations. A $2M working capital adjustment on a $50M deal might seem minor, but it comes directly off the equity check the seller receives.
Enterprise value is most commonly expressed as a multiple of EBITDA. The EV/EBITDA multiple is the universal valuation metric in private equity because it allows apples-to-apples comparison across companies with different capital structures, tax situations, and depreciation schedules. When a fund manager says they “bought at 7x and sold at 9x,” they are referring to EV/EBITDA multiples. The difference between entry and exit multiples is one of three primary return drivers in a leveraged buyout, alongside EBITDA growth and debt paydown.
For a concrete example: a PE firm acquires a company at an enterprise value of $80M (8x on $10M EBITDA), using $50M of debt and $30M of equity. Over five years, the team grows EBITDA to $15M and pays down $15M of debt. At exit, the company sells at 9x EBITDA for an enterprise value of $135M. After repaying the remaining $35M of debt, equity value is $100M, a 3.3x MOIC on the original $30M equity investment.
Understanding the relationship between enterprise value and equity value is essential for fund managers communicating with limited partners. When reporting portfolio company valuations, the relevant metric is typically net asset value (NAV), which is derived from estimated enterprise values less net debt across the portfolio. The methodology for estimating enterprise value of unrealized investments, whether based on comparable public company multiples, precedent transactions, or discounted cash flow, is a regular topic in LP due diligence conversations and a key component of any due diligence questionnaire.
Frequently Asked Questions
What is the difference between enterprise value and equity value?
Enterprise value is the total value of the business to all capital providers, both debt holders and equity holders. Equity value is what is left for shareholders after subtracting net debt. The formula is: Equity Value = Enterprise Value minus Net Debt. In a leveraged buyout, the PE firm pays the enterprise value but only writes an equity check equal to the equity value. The rest comes from debt.
Why do PE firms use EV/EBITDA instead of price-to-earnings?
Price-to-earnings (P/E) ratios are distorted by capital structure, tax strategies, and non-cash charges. Two identical businesses with different debt levels will have different P/E ratios even though they generate the same operating cash flow. EV/EBITDA is capital-structure neutral, making it the standard for comparing acquisition targets across different financing arrangements.
What is a typical EV/EBITDA multiple in private equity?
Multiples vary significantly by industry, company size, growth rate, and market conditions. According to Bain and Pitchbook data, middle-market PE transactions in the US have generally traded between 8-12x EBITDA in recent years. High-growth software or healthcare companies may trade above 15x. Smaller companies in less attractive industries may trade at 5-7x. The multiple reflects the market's assessment of future cash flow growth and risk.
